HIV INFECTIONS

This early-stage study tests three experimental mRNA vaccines designed to teach the body to fight HIV. About 108 healthy, HIV-negative adults aged 18-55 will receive the vaccines to check for safety and whether they produce protective antibodies. The goal is to see if these vacci…

This early-stage trial tests two experimental mRNA vaccines designed to train the immune system to make powerful antibodies that could block HIV. The study involves 53 healthy adults without HIV to check if the vaccines are safe and trigger the desired immune responses. The goal …

This early-phase study tests a new biologic treatment in 20 people with HIV who have no AIDS symptoms. The goal is to see if the therapy can lower the amount of virus in the blood and help the immune system fight HIV better. The treatment is given through the skin, and researcher…

This early-stage study tests a new lab-made antibody called VH4527079 in healthy adults and people with HIV. The goal is to check if it is safe and how the body processes it when given as a shot or IV. About 102 participants will receive one or more doses. This is not a cure; it …

This study tests a program called PASEO that helps teenagers with HIV in Peru move from pediatric to adult care. The program includes a helper who guides them, peer support groups, and mental health check-ins. About 160 teens aged 14-21 will take part to see if the program helps …

This study tests if adding dapagliflozin (a diabetes drug) or a specific statin combo can help people with HIV who have gained weight and have high cholesterol. About 300 adults aged 40-75 on common HIV meds will be randomly assigned to receive either dapagliflozin or a placebo, …

This study looks at three ways to improve HIV treatment for people who inject drugs in India: starting HIV medicine on the same day, getting care at community centers instead of government clinics, and offering extra support if the first treatment doesn't work. About 800 adults w…

This study tests whether a two-medicine HIV treatment (dolutegravir and lamivudine) works as well as the usual three-medicine treatment for children aged 2 to 15 who already have their HIV under control. About 386 children will take part, and researchers will check if the simpler…

This study aimed to find the right dose of a new HIV pill for children aged 3 and older weighing 22 to 55 pounds. The pill combines two medicines to control HIV. However, the study was withdrawn before any participants were enrolled, so no results are available.

This study tests whether a two-drug HIV pill (dolutegravir/lamivudine) works as well as a three-drug pill (bictegravir/emtricitabine/tenofovir alafenamide) for adults who have never taken HIV medication before. About 473 participants will take one of the two daily pills for up to…

This study tests whether a trained friend, family member, or partner can safely give long-acting HIV injections at home. It involves 1,000 people with HIV who are already virally suppressed and have started the injectable treatment. The goal is to make HIV care more convenient an…

This study tested whether adults with HIV whose virus is already suppressed by daily pills can switch to a monthly injection of two long-acting drugs (cabotegravir and rilpivirine) and keep the virus under control. About 618 participants were randomly assigned to either stay on t…

This study tests if adults with HIV who have their virus under control can switch from daily pills to a monthly injection. About 631 participants will either stay on their current pills or switch to the shots. The goal is to see if the shots work just as well at keeping the virus…

This study tests a program that combines social support and digital health tools to help people with HIV who struggle to take their medication regularly. About 210 participants in Taiwan will receive the intervention, and researchers will check if their medication adherence, vira…

This early-phase study tests whether adding an experimental drug (VH3810109) with or without another drug (fostemsavir) to standard HIV therapy can reduce the amount of hidden HIV in the body. About 107 adults with HIV, both newly diagnosed and those already on treatment, will ta…

This study tested whether a combination of a therapeutic vaccine, a broadly neutralizing antibody (10-1074), and a drug called romidepsin could help people with HIV achieve remission, meaning they could stop their daily antiretroviral therapy without the virus rebounding. The tri…

This study tests a new drug, VH3810109, given with another HIV medicine (cabotegravir) in adults whose HIV is already well-controlled. The goal is to see if this combination can keep the virus suppressed as well as standard treatments. About 185 participants will receive the drug…

This study tests whether a program that helps HIV-positive men who have sex with men build supportive social connections can improve their medical care attendance and overall health. One hundred participants in St. Petersburg, Russia, will receive either standard counseling or co…

This study looks at whether having a trained peer case manager can help people with HIV who also have mental health or substance use problems get the care they need. About 405 adults from an HIV clinic will be randomly assigned to either usual care or extra support from a peer. T…

This study looks at 168 people with multidrug-resistant HIV who have few treatment options left. It compares those who get ibalizumab (an injectable antibody) plus other HIV drugs to those who don't get ibalizumab. The goal is to see if ibalizumab helps control the virus better o…

This study tests the safety and proper dosing of three HIV drugs (atazanavir, darunavir, and emtricitabine/tenofovir alafenamide) in children from 4 weeks to under 18 years old who already have the virus under control. The goal is to find the right dose for different age and weig…

This study looks at two different HIV treatments for people who have never taken HIV medication before. Everyone starts with a daily pill (Dolutegravir/Lamivudine) to lower the virus to undetectable levels. Once that happens, participants can choose to either stay on the daily pi…

This study tested whether a long-acting injectable HIV medication works better than daily oral pills for people who have had trouble sticking to their treatment. 456 participants with HIV and a history of poor adherence were enrolled. The goal was to see if the injectable option …

This study gives HIV-1 patients ongoing access to the drug etravirine until they can switch to a local treatment option. It includes 180 participants aged 2 and older who previously benefited from etravirine in a parent trial. The main goal is to monitor safety by tracking any si…

This study tests a clinic-supported mobile health program called Connections for up to 806 HIV patients who also have substance use disorders. Participants get support from their care team and peer mentors for one year to help them stay virally suppressed and attend appointments.…

This study tests a new version of the HIV prevention drug cabotegravir, given as a shot every 4 months. About 229 teens and adults at risk of HIV will receive the injection to see if it keeps drug levels high enough to prevent infection. The goal is to make HIV prevention easier …

This study aims to see if mobile phone messages can help teens aged 15-19 in Uganda prevent HIV and address related issues like mental health and alcohol use. Researchers will adapt an existing text and voice system to include HIV prevention info and mental health checks. The stu…

This study tested whether a long-acting injectable drug (cabotegravir) is safe and effective for preventing HIV in women, compared to taking a daily oral pill (TDF/FTC). Over 3,200 HIV-uninfected women aged 18-45 participated. The goal was to see if the shot could offer a more co…

This study tests a program called TIARAS for women who inject drugs and are already taking PrEP to prevent HIV. Participants are randomly assigned to either write about a past trauma or write about neutral topics, and both groups also receive support to reduce drug use. The goal …

This study tests a smartphone app called Combine designed to help gay, bisexual, and other men who have sex with men in rural southern US get tested for HIV and STIs and start taking PrEP (a daily pill that prevents HIV). About 473 men will be randomly assigned to use the app alo…

This study tests whether text reminders, commitment pledges, and planning prompts can help men who have sex with men stay on PrEP, a daily pill that prevents HIV. About 106 participants in South Africa will either get standard care or these extra nudges. Researchers will check if…

This pilot study tests whether an electronic health record tool can help doctors spot patients at higher risk for HIV and prescribe them pre-exposure prophylaxis (PrEP), a daily pill that prevents HIV. Researchers will roll out the tool in 2-3 community health centers and compare…

This study looks at whether adding communication skills training and a substance use module to standard couples HIV testing can help male couples reduce drug use and risky sexual behaviors. About 484 male couples will be randomly assigned to different combinations of these add-on…

This study tests a comprehensive approach to help high-risk men who have sex with men (MSM) in the southern US get better access to HIV prevention and treatment services. The goal is to increase use of PrEP (a daily pill that prevents HIV) for those without HIV, and improve care …

This study tests whether a structured exercise program can improve physical function and reduce disability in HIV-positive adults aged 50 and older in Côte d'Ivoire. Participants are randomly assigned to a supervised group exercise, a home-based program with phone support, or hea…

This study looks for the best way to screen for cervical cancer in women living with HIV. About 1,000 women from Latin American countries will provide samples and have a detailed exam. The goal is to find which test most accurately identifies precancerous changes that need treatm…

This study uses a special imaging scan (PET/CT) and a radioactive tracer to measure inflammation in the brain. Researchers will compare four groups: people with HIV, people with opioid use disorder, people with both, and healthy volunteers. The goal is to understand how these con…

This study asks people who have taken part in HIV clinical trials for permission to use their stored blood and tissue samples in future research, including genetic tests. The goal is to have a broad consent so scientists can study these samples for many years to come. No new trea…

This study is testing a program called CHIMES to help young Black gay, bisexual, and other men who have sex with men (ages 18-29) who are living with HIV get better access to both HIV care and mental health support. The program will be offered at two clinics in Atlanta. Researche…

This early-stage study is testing the safety and tolerability of an experimental HIV treatment called a capsid inhibitor. It involves 85 healthy adults who receive one or more injections of the drug or a placebo. The goal is to see how the body handles the drug and whether it cau…

This study looks at how healthy adults without HIV tolerate two long-acting injections used to prevent or treat HIV. About 65 participants will receive both shots at different times to compare injection site reactions and overall acceptability. The goal is to understand if people…

This study tests whether computer-assisted X-rays and other simple tests can help find undiagnosed tuberculosis (TB) and COVID-19 in African communities. About 26,200 adults will be screened using these tools to see if they speed up detection and reduce the number of missed cases…